2022-12-11
All-China Federation of Industry & Commerce, Medical& Pharmaceutical Chamber released the “2021 List of Most Influential Corporations in the Chinese Pharmaceutical Industry” online recently. Hanhui Pharma was awarded two honors “2021 Top 50 Fast-growing Chinese Pharmaceutical Enterprises” and “2021 Legal Compliance and Integrity Enterprise in the Chinese Pharmaceutical Industry”; meanwhile, the parent company Hisun Pharmaceuticals won the title of “Top 100 Pharmaceutical Enterprises of China”.
2022-08-03
During the 14th Annual Health China Forum sponsored by People's Daily Health and Health Times released the List of Top Ten New Drugs (in China) on August 3, 2022, Saisimei® (Hybutimibe) awarded the honor. Saisimei® is the only Class I innovative cardiovascular drugs approved in China in recent years, as well as the first cholesterol absorption inhibitor with independent intellectual property rights in China for the treatment of primary hypercholesterolemia.
2022-03-09
Improving the comprehensive average land benefit is important to promote the high-quality development of the manufacturing industry. In front of the increasingly prominent land restriction factors, Hanhui Pharma focuses on high-quality development, competitiveness improvement and modernization, continues to optimize the allocation of resources and elements to precisely facilitate industrial upgrading and technological innovation. Hanhui ranks among the top 10 bio-pharmaceutical enterprises in Zhejiang Province in terms of Comprehensive Average Land Benefit. It is the only bio-pharmaceutical enterprise selected in Fuyang District.
2022-01-24
The first commercial batch of Tazocin® was manufactured by the process steps of charging, on-line weighing, quantitative filling of the sterile solution, automatic delivery of the sterile product to the lyophilizer, and freezing, sublimation, and drying of the sterile solution on January 24, 2022. This is the first time that Hanhui Pharma has realized the localization of injection products, marking a new member of the company's localized products!
2022-01-20
Hanhui Pharma obtained the drug clinical trial approval of HS301 tablets (40 mg and 80 mg) issued by NMPA on January 20, 2022, which means that HS301 tablets is approved to conduct clinical trials in locally advanced or metastatic solid tumors for this product, a milestone in the life circle of Hanhui innovative drug application.
2022-12-11
All-China Federation of Industry & Commerce, Medical& Pharmaceutical Chamber released the “2021 List of Most Influential Corporations in the Chinese Pharmaceutical Industry” online recently. Hanhui Pharma was awarded two honors “2021 Top 50 Fast-growing Chinese Pharmaceutical Enterprises” and “2021 Legal Compliance and Integrity Enterprise in the Chinese Pharmaceutical Industry”; meanwhile, the parent company Hisun Pharmaceuticals won the title of “Top 100 Pharmaceutical Enterprises of China”.
2022-08-03
During the 14th Annual Health China Forum sponsored by People's Daily Health and Health Times released the List of Top Ten New Drugs (in China) on August 3, 2022, Saisimei® (Hybutimibe) awarded the honor. Saisimei® is the only Class I innovative cardiovascular drugs approved in China in recent years, as well as the first cholesterol absorption inhibitor with independent intellectual property rights in China for the treatment of primary hypercholesterolemia.
2022-03-09
Improving the comprehensive average land benefit is important to promote the high-quality development of the manufacturing industry. In front of the increasingly prominent land restriction factors, Hanhui Pharma focuses on high-quality development, competitiveness improvement and modernization, continues to optimize the allocation of resources and elements to precisely facilitate industrial upgrading and technological innovation. Hanhui ranks among the top 10 bio-pharmaceutical enterprises in Zhejiang Province in terms of Comprehensive Average Land Benefit. It is the only bio-pharmaceutical enterprise selected in Fuyang District.
2022-01-24
The first commercial batch of Tazocin® was manufactured by the process steps of charging, on-line weighing, quantitative filling of the sterile solution, automatic delivery of the sterile product to the lyophilizer, and freezing, sublimation, and drying of the sterile solution on January 24, 2022. This is the first time that Hanhui Pharma has realized the localization of injection products, marking a new member of the company's localized products!
2022-01-20
Hanhui Pharma obtained the drug clinical trial approval of HS301 tablets (40 mg and 80 mg) issued by NMPA on January 20, 2022, which means that HS301 tablets is approved to conduct clinical trials in locally advanced or metastatic solid tumors for this product, a milestone in the life circle of Hanhui innovative drug application.
